Research graph
References from Clinical Outcomes of Sacituzumab Govitecan in Breast Cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 · External reference
Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology
10.6004/jnccn.2024.0035 · 2024 · External reference
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer
10.1016/j.esmoop.2023.101541 · 2023 · External reference
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
10.18632/oncotarget.25615 · 2018 · External reference
Strategies and challenges for the next generation of antibody-drug conjugates
10.1038/nrd.2016.268 · 2017 · External reference
Sacituzumab govitecan in metastatic triple-negative breast cancer
10.1056/nejmoa2028485 · 2021 · External reference
Sacituzumab govitecan in hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer
10.1200/jco.22.01002 · 2022 · External reference
Sacituzumab govitecan in untreated, advanced triple-negative breast cancer
10.1056/nejmoa2511734 · 2025 · External reference
Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer
10.1056/nejmoa2508959 · 2026 · External reference
Sacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial
10.1038/s41591-024-03269-z · 2024 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
10.1136/bmj.n71 · 2021 · External reference
SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer
10.1200/jco.2024.42.17_suppl.lba1004 · 2024 · External reference
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
10.1136/bmj.d5928 · 2011 · External reference
Improving GRADE evidence tables part 3: detailed guidance for explanatory footnotes supports creating and understanding GRADE certainty in the evidence judgments
10.1016/j.jclinepi.2015.12.006 · 2016 · External reference
Using Grading of Recommendations Assessment, Development, and Evaluation (GRADE) to rate the certainty of evidence of study outcomes from systematic reviews: a quick tutorial
10.4103/ds.ds-d-22-00154 · 2023 · External reference
Measuring inconsistency in meta-analyses
10.1136/bmj.327.7414.557 · 2003 · External reference
Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression
10.1200/jco.23.01409 · 2024 · External reference
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
10.1016/s0140-6736(23)01245-x · 2023 · External reference
A meta-analysis and systematic review of the first Trop-2-targeting antibody–drug conjugate (sacituzumab govitecan) in treating metastatic breast cancer
10.1007/s00228-025-03876-w · 2025 · External reference
The efficacy and safety of sacituzumab govitecan in the treatment of breast cancer: a systemic review and meta-analysis of emerging clinical data
10.3389/fimmu.2025.1683594 · 2025 · External reference
Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan)
10.1158/1078-0432.ccr-15-0670 · 2015 · External reference
A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer
10.1038/s41416-020-01050-w · 2020 · External reference
The mode of action and clinical outcomes of sacituzumab govitecan in solid tumors
10.1158/1078-0432.ccr-24-1525 · 2025 · External reference
Safety profile of sacituzumab govitecan in patients with breast cancer: a systematic review and meta-analysis
10.1016/j.breast.2024.103853 · 2025 · External reference
Impact of UGT1A1*28 allele on the safety and effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: real-world evidence
10.3390/jcm15020574 · 2026 · External reference
Pre-therapeutic UGT1A1 genotyping in breast cancer patients receiving sacituzumab govitecan to improve safety: a meta-analysis and recommendation
10.1111/cts.70462 · 2026 · External reference
The early safety signal of sacituzumab govitecan-related toxicity and the UGT1A1*28 genotype in metastatic breast cancer: a real-world preliminary report
10.3390/jcm15051715 · 2026 · External reference
Topoisomerase I inhibitors: camptothecins and beyond
10.1038/nrc1977 · 2006 · External reference
Triple-negative breast cancer
10.1056/nejmra1001389 · 2026 · External reference
A meta-analysis and systematic review of the first Trop-2-targeting antibody–drug conjugate (sacituzumab govitecan) in treating metastatic breast cancer
10.1007/s00228-025-03876-w · ExternalCitation · doi-reference
Safety profile of sacituzumab govitecan in patients with breast cancer: a systematic review and meta-analysis
10.1016/j.breast.2024.103853 · ExternalCitation · doi-reference
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer
10.1016/j.esmoop.2023.101541 · ExternalCitation · doi-reference
Improving GRADE evidence tables part 3: detailed guidance for explanatory footnotes supports creating and understanding GRADE certainty in the evidence judgments
10.1016/j.jclinepi.2015.12.006 · ExternalCitation · doi-reference
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
10.1016/s0140-6736(23)01245-x · ExternalCitation · doi-reference
Topoisomerase I inhibitors: camptothecins and beyond
10.1038/nrc1977 · ExternalCitation · doi-reference
Strategies and challenges for the next generation of antibody-drug conjugates
10.1038/nrd.2016.268 · ExternalCitation · doi-reference
A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer
10.1038/s41416-020-01050-w · ExternalCitation · doi-reference
Sacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial
10.1038/s41591-024-03269-z · ExternalCitation · doi-reference
Sacituzumab govitecan in metastatic triple-negative breast cancer
10.1056/nejmoa2028485 · ExternalCitation · doi-reference
Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer
10.1056/nejmoa2508959 · ExternalCitation · doi-reference
Sacituzumab govitecan in untreated, advanced triple-negative breast cancer
10.1056/nejmoa2511734 · ExternalCitation · doi-reference
Triple-negative breast cancer
10.1056/nejmra1001389 · ExternalCitation · doi-reference
Pre-therapeutic UGT1A1 genotyping in breast cancer patients receiving sacituzumab govitecan to improve safety: a meta-analysis and recommendation
10.1111/cts.70462 · ExternalCitation · doi-reference
Measuring inconsistency in meta-analyses
10.1136/bmj.327.7414.557 · ExternalCitation · doi-reference
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
10.1136/bmj.d5928 · ExternalCitation · doi-reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
10.1136/bmj.n71 · ExternalCitation · doi-reference
Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan)
10.1158/1078-0432.ccr-15-0670 · ExternalCitation · doi-reference
The mode of action and clinical outcomes of sacituzumab govitecan in solid tumors
10.1158/1078-0432.ccr-24-1525 · ExternalCitation · doi-reference
SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer
10.1200/jco.2024.42.17_suppl.lba1004 · ExternalCitation · doi-reference
Sacituzumab govitecan in hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer
10.1200/jco.22.01002 · ExternalCitation · doi-reference
Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression
10.1200/jco.23.01409 · ExternalCitation · doi-reference
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
10.18632/oncotarget.25615 · ExternalCitation · doi-reference
The efficacy and safety of sacituzumab govitecan in the treatment of breast cancer: a systemic review and meta-analysis of emerging clinical data
10.3389/fimmu.2025.1683594 · ExternalCitation · doi-reference
Impact of UGT1A1*28 allele on the safety and effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: real-world evidence
10.3390/jcm15020574 · ExternalCitation · doi-reference
The early safety signal of sacituzumab govitecan-related toxicity and the UGT1A1*28 genotype in metastatic breast cancer: a real-world preliminary report
10.3390/jcm15051715 · ExternalCitation · doi-reference
Using Grading of Recommendations Assessment, Development, and Evaluation (GRADE) to rate the certainty of evidence of study outcomes from systematic reviews: a quick tutorial
10.4103/ds.ds-d-22-00154 · ExternalCitation · doi-reference
Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology
10.6004/jnccn.2024.0035 · ExternalCitation · doi-reference
